Fig 3.

Post hoc analysis and forest plots of time to recurrence and overall survival hazard ratios with 95% CIs to assess the impact of noncompliance with assigned therapy in the arm treated with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). Compliant excludes patients who refused assigned treatment; as treated includes all patients and analyzes them according to treatment received; 4-month and 6-month landmark analyses assessed only those patients in each arm as assigned who survived without recurrence to a 4- or 6-month landmark, respectively; and ITT represents protocol-specified intent-to-treat analysis.